Information  X 
Enter a valid email address

FastForward Inn Ltd (FFWD)


Friday 28 May, 2021

FastForward Inn Ltd

Investee Company Update: Little Green Pharma

RNS Number : 1118A
FastForward Innovations Limited
28 May 2021



FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

28 May 2021

FastForward Innovations Ltd

("FastForward", "FFWD" or the "Company")


Investee Company Update: Little Green Pharma Ltd


FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to note that Little Green Pharma Ltd ('LGP') has announced an additional A$2.5m purchase order for LGP's high THC cannabis flower medicine from German pharmaceutical wholesaler Deutsche Medizinalcannabis GmbH ('DEMECAN'}. The purchase order is for delivery in the quarter ended 31 December 2021 and follows consistent growth in size of quarterly DEMECAN purchase orders. The increased order reflects the demand from Germany and the confidence in LGP's quality and supply.

Ed McDermott, CEO of FastForward Innovations, commented: "As one of our most recent investments in the medicinal cannabis space, we are pleased to note the progress being made in Little Green Pharma's strategy to increase patient access to medicinal cannabis. The further order from DEMECAN in Germany demonstrates the increasing global demand for LGP's GMP-grade medicinal cannabis products and we look forward to further positive updates from LGP."  


The announcement is set out below without material changes or adjustments other than for the inclusion of links and can be viewed in full on LGP's website via the following link:


27 May 2021

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce the receipt of an additional firm purchase order for ~21,300 units of the Company's high-THC medicinal cannabis flower medicine from German pharmaceutical wholesaler Deutsche Medizinalcannabis GmbH ("DEMECAN"). The purchase order has a value of $2.5m and represents ~320kg of flower for delivery during the quarter ending 31 December 2021.

LGP's Managing Director, Fleta Solomon, commented that:

"This order means a lot more than just the value of the sales it represents, it's tangible evidence of the success of our strategy. We are currently in a position where all flower product we produce is sold into Australia and overseas markets and we have customers looking for more. It heightens the urgency for us to focus on increasing our production capacity to capitalize on the brand equity we have built in the market. "


This is the fourth purchase order received from DEMECAN, following previous quarterly orders of 500, 9,000, and 17,000 units for delivery in CYQ1, Q2, and Q3 of 2021, respectively. DEMECAN has now ordered a total of ~47,800 units of LGP medicines which would bring the total revenue for CY2021 to ~$5.7m from DEMECAN alone. The annualised run-rate based on this CYQ4 order would be ~1,300kgs per annum, which would significantly exceed the original target run-rate of 1,000kgs per annum under the medicinal cannabis purchase agreement (refer ASX announcement dated 27 February 2020), and would bring the total annualized DEMECAN revenues to ~$10.2m per annum.

The Company has brought its existing cultivation facilities to full capacity in order to capitalise on growing demand in the German market, as well as increasing demand from Australian and other offshore markets.

Alistair Warren

Company Secretary

Little Green Pharma

E: [email protected]  

M: +61 8 6280 0050

Fleta Solomon

Managing Director

Little Green Pharma

E: [email protected]  

M: +41 782 260 200  

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to:

*** ENDS***

For further information on the Company please visit   or contact:

Ed McDermott / Lance de Jersey

FastForward Innovations Ltd

Email: [email protected]  


James Biddle / Roland Cornish

Beaumont Cornish Limited,



Tel: +44 (0) 207 628 3396


Isabella Pierre / Damon Heath

Shard Capital Partners LLP


T: +44 (0)20 7186 9927

Isabel de Salis / Charlotte Hollinshead

St Brides Partners Ltd,

Financial PR


Email: [email protected]



FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.





This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t